X0202 SCHEDULE 13G 0002077247 XXXXXXXX LIVE Common Stock, $0.0001 par value per share 08/03/2026 0001736730 Camp4 Therapeutics Corp 13463J101 One Kendall Square, Building 1400 West, 3rd Floor. Cambridge MA 02139 Rule 13d-1(c) Trails Edge Capital Partners, LP DE 3790636.00 0.00 3790636.00 0.00 3790636.00 N 6 IA PN See Item 4 for additional information. Trails Edge Biotechnology Master Fund, LP E9 3790636.00 0.00 3790636.00 0.00 3790636.00 N 6 PN See Item 4 for additional information. Ortav Yehudai X1 3790636.00 0.00 3790636.00 0.00 3790636.00 N 6 IN See Item 4 for additional information. Camp4 Therapeutics Corp One Kendall Square, Building 1400 West, 3rd Floor. Cambridge, MA 02139. This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers". The address for each Filer is 3445 Peachtree Road NE, Suite 900, Atlanta, GA 30326. See Item 4 of the cover page of each Filer. Y As of August 3, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 3,790,636 Common Stock, $0.0001 par value per share (the "Shares"), of Camp4 Therapeutics Corporation (the "Issuer"). The 3,790,636 Shares reported as beneficially owned on this Schedule 13G by each Filer consist of 3,790,636 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns approximately 6% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own approximately 6% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 62,753,200 Shares issued and outstanding as of August 3, 2026, as reported by the Issuer in its Registration Statement on Form S-3, filed with the Securities and Exchange Commission on August 6, 2026. 6% 3,790,636.00 0 3,790,636.00 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1- Joint Filing Agreement Trails Edge Capital Partners, LP /s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai 08/10/2026 Trails Edge Biotechnology Master Fund, LP /s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai 08/10/2026 Ortav Yehudai /s/ Ortav Yehudai 08/10/2026